|
|
|
|
| LEADER |
00000cam a2200000 a 4500 |
| 001 |
1617902 |
| 003 |
ICU |
| 005 |
20020106120600.0 |
| 008 |
940520s1994 sz a b 001 0 eng d |
| 010 |
|
|
|a 94136937
|
| 020 |
|
|
|a 3805558562
|
| 035 |
|
|
|a (ICU)BID18673837
|
| 035 |
|
|
|a (OCoLC)29772304
|
| 040 |
|
|
|a MWMU
|c MWMU
|d DLC$dOrLoB
|
| 041 |
1 |
|
|a eng
|h fre
|
| 042 |
|
|
|a lccopycat
|
| 050 |
0 |
0 |
|a RM301.27
|b .S6813 1994
|
| 060 |
|
0 |
|a QV 771
|b S769m 1994a
|
| 082 |
|
|
|a 615/.1901
|2 20
|
| 100 |
1 |
|
|a Spriet, Alain
|0 http://id.loc.gov/authorities/names/n84133824
|1 http://viaf.org/viaf/7397229
|
| 240 |
1 |
0 |
|a Méthodologie des essais cliniques des médicaments.
|l English
|
| 245 |
1 |
0 |
|a Methodology of clinical drug trials /
|c Alain Spriet, Thérèse Dupin-Spriet, Pierre Simon ; translated by Robert Coluzzi ... [et al.] ; with a preface by Fernand Sauer.
|
| 250 |
|
|
|a 2nd, rev. ed.
|
| 260 |
|
|
|a Basel ;
|a New York :
|b Karger,
|c c1994.
|
| 300 |
|
|
|a viii, 269 p. :
|b ill. ;
|c 25 cm.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|0 http://id.loc.gov/vocabulary/contentTypes/txt
|
| 337 |
|
|
|a unmediated
|b n
|2 rdamedia
|0 http://id.loc.gov/vocabulary/mediaTypes/n
|
| 338 |
|
|
|a volume
|b nc
|2 rdacarrier
|0 http://id.loc.gov/vocabulary/carriers/nc
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 505 |
0 |
0 |
|g 1.
|t Introduction --
|g 2.
|t Principles of the controlled trial --
|g 3.
|t Selection of subjects --
|g 4.
|t Efficacy assessment --
|g 5.
|t Randomization --
|g 6.
|t Single-blind and double-blind trials --
|g 7.
|t Choice of the comparator: placebo or active drug? --
|g 8.
|t Dosage and therapeutic schema --
|g 9.
|t Experimental designs --
|g 10.
|t Subjects lost to follow-up --
|g 11.
|t Patient compliance and discontinuation of treatment --
|g 12.
|t Case report forms --
|g 13.
|t Multicenter trials --
|g 14.
|t Imperfect data analysis --
|g 15.
|t Confirmatory analysis of the principal evaluation criterion --
|g 16.
|t Interim analyses --
|g 17.
|t Exploratory analyses --
|g 18.
|t Pragmatic trials. Decision methods --
|g 19.
|t Safety data --
|g 20.
|t Sample size --
|g 21.
|t Prudence and protection of participants --
|g 22.
|t Preparing a protocol --
|g 23.
|t Index.
|
| 583 |
1 |
|
|a committed to retain
|c 20170930
|d 20421213
|f HathiTrust
|5 ICU
|
| 650 |
|
0 |
|a Drugs
|x Testing
|x Methodology.
|
| 650 |
|
2 |
|a Clinical Trials
|x methods
|
| 650 |
|
2 |
|a Drug Evaluation
|x methods
|
| 650 |
|
7 |
|a Drugs
|x Testing
|x Methodology.
|2 fast
|0 http://id.worldcat.org/fast/fst00898947
|
| 700 |
2 |
0 |
|a Dupin-Spriet, Thérèse
|0 http://id.loc.gov/authorities/names/n92102774
|1 http://viaf.org/viaf/32037688
|
| 700 |
1 |
0 |
|a Simon, Pierre,
|c M.D.
|0 http://id.loc.gov/authorities/names/n84133825
|1 http://viaf.org/viaf/189397871
|
| 850 |
|
|
|a ICU
|
| 901 |
|
|
|a ToCBNA
|
| 903 |
|
|
|a HeVa
|
| 903 |
|
|
|a Hathi
|
| 929 |
|
|
|a cat
|
| 999 |
f |
f |
|i 172c45d0-137d-5565-a2b8-89e605afc5b4
|s cdb47dcc-f045-5ee1-a834-1b4dbcb18989
|
| 928 |
|
|
|t Library of Congress classification
|a RM301.27.S68130 1994
|l JCL
|c JCL-Sci
|i 2750231
|
| 927 |
|
|
|t Library of Congress classification
|a RM301.27.S68130 1994
|l JCL
|c JCL-Sci
|e CRERAR
|b 39835184
|i 3063922
|
